Beyond their biological significance, several of these enriched pathways—such as estrogen signaling, PI3K-Akt signaling, Wnt signaling, and endocrine resistance—are therapeutically actionable and have been linked to treatment resistance in prostate cancer. The gene discussed is AKT1; the disease is prostate carcinoma.